Clene Nanomedicine to Present Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2022
February 18, 2022 07:00 ET
|
Clene, Inc.
SALT LAKE CITY, Feb. 18, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Nanomedicine Provides Clinical Program Update
February 14, 2022 07:00 ET
|
Clene, Inc.
Healey ALS Platform Trial fully enrolled; top-line data expected 2H 2022Significant survival benefit from RESCUE-ALS open label extension (OLE) Phase 2 trial to be presented at upcoming Muscular...
Clene Announces New Chief Financial Officer Morgan Brown
February 01, 2022 07:00 ET
|
Clene, Inc.
SALT LAKE CITY, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Nanomedicine’s Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial
January 18, 2022 07:00 ET
|
Clene, Inc.
Topline data is expected in 1H 2022Trial is evaluating acutely symptomatic, non-hospitalized COVID-19 patients in Brazil CNM-ZnAg is a proprietary zinc-silver ionic solution that has demonstrated both...
Clene Nanomedicine Presents Blinded Interim Update from VISIONARY-MS and Positive Results from REPAIR-MS Phase 2 Clinical Trials
October 14, 2021 07:00 ET
|
Clene Nanomedicine, Inc.
VISIONARY-MS blinded interim data show clinically relevant improvements in the modified MS Functional Composite for the study population through 48 weeks of treatment REPAIR-MS clinical trial...